The inclusion of biosimilars on the PBS is a cost-saving measure aimed at reducing healthcare expenses while maintaining high standards of patient care. By offering these cost-effective alternatives, the PBS allows patients with chronic conditions, such as rheumatoid arthritis, cancer, and diabetes, to access effective treatments at a lower price. Given that biological drugs often come with high price tags, biosimilars offer a financially sustainable solution, fostering greater patient access to essential treatments and ensuring the long-term viability of the healthcare system. 

On 1 October 2024, Australia’s Department of Health and Aged Care released an updated list of biosimilar medicines subsidised on the PBS, see Table 1. 

Altogether, 12 active ingredients of biosimilars are represented across 30 brands on the PBS. This includes all approved biosimilars for adalimumab (6), filgrastim (2), infliximab (2), pegfilgrastim (2), rituximab (3), each marked as ‘a’ flagged, as well as enoxaparin sodium, etanercept, and follitropin alfa biosimilars, also marked as ‘a’ flagged. In total, 18 biosimilars have been ‘a’ flagged, signifying they are offered at reduced prices compared to their originator biological. Notably, a statutory price reduction of up to 25% applies to all brands of a medicine after its first generic or biosimilar version is PBS listed [1].

The Australian government has collaborated closely with healthcare providers, including doctors and pharmacists, to encourage the adoption of biosimilars. Consequently, the PBS continues to expand its listing of these medicines, promoting wider use across the healthcare sector.

Related articles
Australia and EU: Alvotech Humira and Stada Lucentis biosimilars approved

Australia introduces new bill to address drug shortages

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars in Australia – a-flagging and sustainability [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Nov 20]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-in-Australia-a-flagging-and-sustainability

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.